Yi Larson
2021 - Turning Point Therapeutics
In 2021, Yi Larson earned a total compensation of $3.9M as Former Executive Vice President and Chief Financial Officer at Turning Point Therapeutics, a 72% increase compared to previous year.
Compensation breakdown
| Option Awards | $1,996,207 |
|---|---|
| Salary | $109,789 |
| Stock Awards | $1,766,506 |
| Total | $3,872,502 |
Larson received $2M in option awards, accounting for 52% of the total pay in 2021.
Larson also received $109.8K in salary and $1.8M in stock awards.
Rankings
In 2021, Yi Larson's compensation ranked 3,454th out of 12,406 executives tracked by ExecPay. In other words, Larson earned more than 72.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,454 out of 12,406 | 72nd |
Division Manufacturing | 1,409 out of 5,492 | 74th |
Major group Chemicals And Allied Products | 568 out of 2,368 | 76th |
Industry group Drugs | 506 out of 2,089 | 76th |
Industry Pharmaceutical Preparations | 352 out of 1,536 | 77th |
Source: SEC filing on April 29, 2022.
Larson's colleagues
We found six more compensation records of executives who worked with Yi Larson at Turning Point Therapeutics in 2021.
2021
Athena Countouriotis
Turning Point Therapeutics
Chief Executive Officer
2021
Mohammad Hirmand
Turning Point Therapeutics
Chief Medical Officer
2021
Annette North
Turning Point Therapeutics
General Counsel
2021
Paolo Tombesi
Turning Point Therapeutics
Chief Financial Officer
2021
Siegfried PHD
Turning Point Therapeutics
Chief Scientific Officer
2021
Brian Baker
Turning Point Therapeutics